Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, George V, Tran, Chris, Mellinghoff, Ingo K, Welsbie, Derek S, Chan, Emily, Fueger, Barbara, Czernin, Johannes, Sawyers, Charles L·2006·Nature Medicine

DOI 10.1038/nm1337

Cited by (605)

Items 301–400 of 605

Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
Ming Yue Li, Chunliu Mi, Ke Si Wang, Zhe Wang, Hong Xiang Zuo, Lian Xun Piao, Guang Hua Xu, Xuezheng Li, Juan Ma, Xuejun Jin · 2017 · Chemico-Biological Interactions
Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy
Jing Ying Tan, Qiang Yu · 2013 · 癌症：英文版
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
Daniel Cejka, Claudia Kuntner, Matthias Preusser, M Fritzer-Szekeres, Barbara J. Fueger, Sabine Strommer, Johannes M. Werzowa, Thorsten Fuereder, Thomas Wanek, Maria Zsebedics et al. · 2009 · British Journal of Cancer
Perillyl alcohol efficiently scavenges activity of cellular ROS and inhibits the translational expression of hypoxia-inducible factor-1α via mTOR/4E-BP1 signaling pathways
Juan Ma, Jing Li, Ke Si Wang, Chunliu Mi, Lian Xun Piao, Guang Hua Xu, Xuezheng Li, Jung Joon Lee, Xuejun Jin · 2016 · International Immunopharmacology
Two-photon fluorescent probe for detection of nitroreductase and hypoxia-specific microenvironment of cancer stem cell
Yajing Liu, Wei Liu, Hongjuan Li, Weixiao Yan, Xinjian Yang, Dandan Liu, Shuxiang Wang, Jinchao Zhang · 2018 · Analytica Chimica Acta
Endothelial Deletion of Phospholipase D2 Reduces Hypoxic Response and Pathological Angiogenesis
Jaewang Ghim, Jin-Sook Moon, Chang Sup Lee, Junyeop Lee, Parkyong Song, Areum Lee, Jin-Hyeok Jang, Dayea Kim, Jong Hyuk Yoon, Young Jun Koh et al. · 2014 · Arteriosclerosis Thrombosis and Vascular Biology
Systemic Therapy for Metastatic Renal Cell Carcinoma
Glenn Scott Kroog, Robert John Motzer · 2008 · Urologic Clinics of North America
Targeting mTOR in cancer: renal cell is just a beginning
Hamdy A. Azim, Hatem A. Azim, Bernard J. Escudier · 2010 · Targeted Oncology
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma
Antoine Thiery-Vuillemin, Guillaume Mouillet, T. Nguyen Tan Hon, Philippe Montcuquet, Tristan Maurina, Hamadi Almotlak, Ulrich Stein, Damien Montange, Audrey Foubert, Virginie Nerich et al. · 2014 · Cancer Chemotherapy and Pharmacology
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
Marina Dusevic Kaymakcalan, Youjin Je, Guru Sonpavde, Matthew D. Galsky, Paul Linh Nguyen, Daniel Y.C. Heng, C J Richards, Toni K. Choueiri · 2013 · British Journal of Cancer
Kinases as Upstream Regulators of the HIF System: Their Emerging Potential as Anti-Cancer Drug Targets
Elitsa Y. Dimova, Carine Michiels, Thomas Kietzmann · 2009 · Current Pharmaceutical Design
Identification of a diverse synthetic abietane diterpenoid library and insight into the structure-activity relationships for antibacterial activity
Wei Hou, Guanjun Zhang, Zhi Luo, Di Li, Haoqiang Ruan, Benfang Helen Ruan, Lin Su, Hongtao Xu · 2017 · Bioorganic & Medicinal Chemistry Letters
Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells
Kazuki Okubo, Makoto Isono, Takako Asano, Akinori Sato · 2019 · Anticancer Research
Hypoxia-Inducible Factor-1 Facilitates Cervical Cancer Progression in Human Papillomavirus Type 16 Transgenic Mice
Zhi Hong Lu, Jason Dennis Wright, Brian A. Belt, Robert D. Cardiff, Jeffrey M. Arbeit · 2007 · American Journal Of Pathology
Downregulation of the W erner syndrome protein induces a metabolic shift that compromises redox homeostasis and limits proliferation of cancer cells
Baomin Li, Juan Manuel Iglesias‐Pedraz, Leng‐Ying Chen, Fei Yin, Enrique Cadenas, S Reddy, Lucio Comai · 2013 · Aging Cell
Gramicidin A Induces Metabolic Dysfunction and Energy Depletion Leading to Cell Death in Renal Cell Carcinoma Cells
Justin M. David, Tori A. Owens, Sonali P. Barwe, Ayyappan K. Rajasekaran · 2013 · Molecular Cancer Therapeutics
Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.
Mette Munk Jensen, Andreas Kjær · 2015 · Europe PMC (PubMed Central)
TGFβ-Induced Deptor Suppression Recruits mTORC1 and Not mTORC2 to Enhance Collagen I (α2) Gene Expression
Falguni Das, Amit Bera, Nandini Ghosh‐Choudhury, Hanna E. Abboud, Balakuntalam S. Kasinath, Goutam Ghosh Choudhury · 2014 · PLoS ONE
Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials
John S. Lam, Allan J. Pantuck, Arie S. Belldegrun, Robert A. Figlin · 2007 · Clinical Cancer Research
Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies
Hannah F. Kyle, Kate F. Wickson, Jonathan Stott, George M. Burslem, Alexander L. Breeze, Christian Tiede, Darren Charles Tomlinson, Stuart L. Warriner, Adam S. Nelson, Andrew John Wilson et al. · 2015 · Molecular BioSystems
Epigenetic silencing of Na,K-ATPase β1subunit geneATP1B1by methylation in clear cell renal cell carcinoma
Ponniah Selvakumar, Tori A. Owens, Justin M. David, Nicholas James Petrelli, Brock C. Christensen, Ashakumary Lakshmikuttyamma, Ayyappan K. Rajasekaran · 2014 · Epigenetics
The Antioxidant N-Acetylcysteine Prevents HIF-1 Stabilization under Hypoxia In Vitro but Does Not Affect Tumorigenesis in Multiple Breast Cancer Models In Vivo
Jaclyn Sceneay, Mira C.P. Liu, Anna Chen, Christina S.F. Wong, David D.L. Bowtell, Andreas Möller · 2013 · PLoS ONE
Profiling mTOR pathway in neuroendocrine tumors
Sara Cingarlini, Maria Bonomi, Vincenzo Corbo, Aldo Scarpa, Giampaolo Tortora · 2012 · Targeted Oncology
Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer
Tomoya Mizuno, Takao Kamai, Hideyuki Abe, Setsu Sakamoto, Kazuhiro Kitajima, Daisaku Nishihara, Hideo Yuki, Tsunehito Kambara, Hironori Betsunoh, Masahiro Yashi et al. · 2015 · BMC Cancer
Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors
Seraina Faes, Anne Planche, Émilie Uldry, Tania Santoro, Catherine Pythoud, Jean‐Christophe Stehle, Janine Horlbeck, Igor Letovanec, Nicolò Riggi, Dipak B. Datta et al. · 2016 · Oncotarget
Intracellular parasitism withToxoplasma gondiistimulates mammalian-target-of-rapamycin-dependent host cell growth despite impaired signalling to S6K1 and 4E-BP1
Yubao Wang, Louis M. Weiss, Amos Orlofsky · 2009 · Cellular Microbiology
Use of Pharmacokinetic/Pharmacodynamic Biomarkers to Support Rational Cancer Drug Development
Debashis Sarker, Simon Pacey, Paul Workman · 2007 · Biomarkers in Medicine
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy- d -glucose under hypoxia in lung cancer cell lines
Medhi Wangpaichitr, Niramol Savaraj, Johnathan C. Maher, Metin Kurtoğlu, Théodore J. Lampidis · 2008 · Molecular Cancer Therapeutics
The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition
Anne Boulay, Heidi A. Lane · 2007 · Springer eBooks
Building high-resolution synthetic lethal networks: a ‘Google map’ of the cancer cell
James Paul, Shaina D'Lee Templeton, Akanksha Baharani, Andrew Freywald, Franco J. Vizeacoumar · 2014 · Trends in Molecular Medicine
What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Emiliano Calvo, Alain Ravaud, Joaquim Bellmunt B · 2012 · Cancer Treatment Reviews
Ouabain suppresses the growth and migration abilities of glioma U‑87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF‑1α
Xiaosa Yang, Zhongwei Xu, Tailong Yi, Rui‐Cheng Xu, Jie Li, Wen‑Bin Zhang, Sai Zhang, Hongtao Sun, Zeqi Yu, Haoxiang Xu et al. · 2018 · Molecular Medicine Reports
Temsirolimus for advanced renal cell carcinoma
Lothar Bergmann, Luise Maute, M. Guschmann · 2013 · Expert Review of Anticancer Therapy
Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk
Xiang Shu, Jie Ming Lin, Christopher G. Wood, Nizar M. Tannir, Xifeng Wu · 2013 · JNCI Journal of the National Cancer Institute
High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma
Nicholas C. Wolff, Andrea Pavía-Jiménez, Vanina Toffessi Tcheuyap, Shane Alexander, Mridula Vishwanath, Alana L. Christie, Xian-Jin Xie, Noelle Sevilir Williams, Payal Kapur, Bruce A. Posner et al. · 2015 · Oncotarget
12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway
Ying Yang, HUAN CONG, Cuicui Han, Liling Yue, Haiying Dong, Jicheng Liu · 2015 · Oncology Reports
Treatment selection for patients with metastatic renal cell carcinoma
Michael B. Atkins, Toni K. Choueiri, Daniel Cho, Meredith M. Regan, Sabina Signoretti · 2009 · Cancer
Metabolic Regulation in Mitochondria and Drug Resistance
Yue Pan, Min Cao, Jianzhou Liu, Qing Kun Yang, Xiaoyu Miao, Vay Liang W. Go, Paul W. N. Lee, Gary Guishan Xiao · 2017 · Advances in experimental medicine and biology
Biological correlation of ¹⁸F-FDG uptake on PET in pulmonary neuroendocrine tumors.
Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Yasuhisa Ohde, Tateaki Naito, Haruhiko Kondo, Takashi Nakajima, Nobuyuki Yamamoto, Toshiaki Takahashi · 2013 · PubMed
Targeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells
Patrick D. Sutphin, Denise A. Chan, James M. Li, Sandra Turcotte, Adam J. Krieg, Amato J. Giaccia · 2007 · Cancer Research
Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α
Juan Ma, Ying Zi Jiang, Hui Rong Shi, Chunliu Mi, Jing Li, Ji‐Xing Nan, Xue Zhen Wu, Jung Joon Lee, Xuejun Jin · 2013 · European Journal of Pharmacology
Renal cancer: Oxygen meets metabolism
Volker H. Haase · 2012 · Experimental Cell Research
mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Daniel Cejka, Matthias Preusser, Thorsten Fuereder, Wolfgang Sieghart, Johannes M. Werzowa, Sabine Strommer, Volker Wacheck · 2008 · PubMed
Role of the ubiquitin proteasome system in renal cell carcinoma
Paul Gettys Corn · 2007 · BMC Biochemistry
Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series
Gianluigi Lunardi, Andrea Armirotti, Maurizio Nicodemo, Lucia Cavallini, Gianluca Damonte, Maria Ornella Vannozzi, Marco Venturini · 2009 · Clinical Therapeutics
Resistance to angiogenesis inhibitors in renal cell carcinoma.
Ila Tamaskar, Jaspreet Dhillon, Роберто Пили · 2011 · PubMed
A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma
Rhonda Lynn Bitting, Patrick N Healy, Patricia A. Creel, James D. Turnbull, Karla K. Morris, Sarah Yenser Wood, Herbert I. Hurwitz, Mark D. Starr, Andrew B. Nixon, Andrew J. Armstrong et al. · 2013 · Clinical Genitourinary Cancer
AMPK activation—protean potential for boosting healthspan
Mark Frederick McCarty · 2013 · AGE
Therapeutic challenges in renal cell carcinoma.
Justin C. Penticuff, Natasha Kyprianou · 2015 · Europe PMC (PubMed Central)
Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies.
Parvin Ataie-Kachoie, Mohammad H. Pourgholami, Farnaz Bahrami-B, Samina Badar, David Lawson Morris · 2015 · Europe PMC (PubMed Central)
Models of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics
Shapiro, Daniel D., Virumbrales-Muñoz, Maria, Beebe, David J., Abel, E. Jason · 2022 · Frontiers in Oncology
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy
George Dranitsaris, Susanne Schmitz, Reuben James Broom · 2013 · Journal of Cancer Research and Clinical Oncology
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
Rosalie Anne Fisher, James Larkin, Charles Swanton · 2011 · The EPMA Journal
A survey of therapy for advanced renal cell carcinoma
Michele Basso, Alessandra Cassano, Carlo Barone · 2009 · Urologic Oncology Seminars and Original Investigations
Gramicidin A Blocks Tumor Growth and Angiogenesis through Inhibition of Hypoxia-Inducible Factor in Renal Cell Carcinoma
Justin M. David, Tori A. Owens, Landon J. Inge, Ross Macrae Bremner, Ayyappan K. Rajasekaran · 2014 · Molecular Cancer Therapeutics
Regulation of glucose metabolism by p62/SQSTM1 through HIF1α
Ke Chen, Jin Zeng, Haibing Xiao, Chunhua Huang, Junhui Hu, Weimin Yao, Yu Gan, Wei Xiao, Hua Xu, Zhangqun Ye · 2016 · Journal of Cell Science
Changing biological behaviour of NETs during the evolution of the disease: progress on progression
Krystallenia Alexandraki, Ariadni Spyroglou, Stylianos Kykalos, Kosmas Daskalakis, Georgios Kyriakopoulos, Georgios Charalambos Sotiropoulos, Gregory Kaltsas, Ashley Barry Grossman · 2021 · Endocrine Related Cancer
Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside
Chiara Alessandra Cella, Saverio Minucci, Francesca Spada, Salvatore Galdy, Mohamed Elgendy, Paola Simona Ravenda, Maria Giulia Zampino, Sabina Murgioni, Nicola Fazio · 2015 · Cancer Treatment Reviews
Targeting the Mammalian Target of Rapamycin in Lung Cancer
Glenn W. Vicary, Jesse Roman · 2016 · The American Journal of the Medical Sciences
Prise en charge du cancer rénal métastatique
A. Méjean, Thierry Lebrét · 2008 · The French Journal of Urology
The solid tumor microenvironment and related targeting strategies: a concise review
Yingliang Wang, Huimin Zhou, Shuguang Ju, Xiangjun Dong, Chuansheng Zheng · 2025 · Frontiers in Immunology
Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions
Sabina Signoretti, Gennady Bratslavsky, Fred Waldman, Victor E. Reuter, John R. Haaga, Maria J. Merino, GEORGE V. THOMAS, Michael R. Pins, Towia A. Libermann, John Williams Gillespie et al. · 2008 · Clinical Cancer Research
Potent Inhibition of HIF1α and p300 Interaction by a Constrained Peptide Derived from CITED2
Xuan Qin, Hailing Chen, Licheng Tu, Yue Ma, Na Liu, Haowei Zhang, Di Li, Bernd Riedl, Donald E. Bierer, Feng Yin et al. · 2021 · Journal of Medicinal Chemistry
Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?
Rosalie Anne Fisher, James Larkin, Charles Swanton · 2012 · Frontiers in Oncology
Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin
Charles Truillet, John T. Cunningham, Matthew F.L. Parker, Loc T. Huynh, Crystal S. Conn, Davide Ruggero, Jason Stuart Lewis, Michael J. Evans · 2016 · Clinical Cancer Research
Allogeneic adipose-derived stem cells suppress mTORC1 pathway in a murine model of systemic lupus erythematosus
Shanshan Wei, S Xie, Zhenghui Yang, Xiaohong Peng, L Gong, Ke‐seng Zhao, Kang Zeng, Kuan Lai · 2018 · Lupus
Naringin Targets NFKB1 to Alleviate Oxygen-Glucose Deprivation/Reoxygenation–Induced Injury in PC12 Cells Via Modulating HIF-1α/AKT/mTOR-Signaling Pathway
Wei Cao, She-Jun Feng, Minchen Kan · 2020 · Journal of Molecular Neuroscience
Review: Updates on novel therapies for metastatic renal cell carcinoma
Kevin Dale Courtney, Toni K. Choueiri · 2010 · Therapeutic Advances in Medical Oncology
The von Hippel–Lindau Tumor Suppressor Protein
William G. Kaelin · 2018 · Annual Review of Cancer Biology
Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma
Leigh Ellis, Preeti Shah, Hans J. Hammers, Kristin Lehet, Paula C. Sotomayor, Gissou Azabdaftari, Mukund Seshadri, Роберто Пили · 2011 · Molecular Cancer Therapeutics
16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development
Aurélie Ducès, Racha Karaky, Dominique Martel-Renoir, Lluis M. Mir, Yamina Hamma‐Kourbali, Ivan Bièche, Paule Opolon, Jean Delbé, José Courty, Michel Perricaudet et al. · 2008 · Molecular Cancer Therapeutics
Synthesis and antimicrobial activity of novel amphiphilic aromatic amino alcohols
Angelina Maria de Almeida, Thiago César Nascimento, Bianca Silva Ferreira, Pedro Pôssa de Castro, Vânia Lúcia da Silva, Cláudio Galuppo Diniz, Mireille Le Hyaric · 2013 · Bioorganic & Medicinal Chemistry Letters
Renal Epithelial Neoplasms: Diagnostic Applications of Gene Expression Profiling
Andrew N. Young, Viraj A. Master, Gladell P. Paner, May Dongmei Wang, Mahul B. Amin · 2008 · Advances in Anatomic Pathology
MRI with Magnetic Nanoparticles Monitors Downstream Anti-Angiogenic Effects of mTOR Inhibition
Alexander R. Guimarães, Robert W. Ross, Jose L. Figuereido, Peter R. Waterman, Ralph Weissleder · 2010 · Molecular Imaging and Biology
ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma
Jennifer S. Carew, Juan Esquivel, Claudia M. Espitia, Christoph M. Schultes, Marcel Mülbaier, Joe Lewis, Bernd Janssen, Francis Joseph Giles, Steffan T. Nawrocki · 2012 · PLoS ONE
Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells
Qinjie Weng, Jun Zhang, Ji Cao, Qing Xia, Duoduo Wang, Yongzhou Hu, Rong Sheng, Honghai Wu, Difeng Zhu, Hong Zhu et al. · 2010 · Investigational New Drugs
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC
Robert A. Figlin · 2008 · Nature Clinical Practice Oncology
mTOR signaling regulates multiple metabolic pathways in human lung fibroblasts after TGF-β and in pulmonary fibrosis
Kun Woo D Shin, Volkan Atalay, Rengül Çetin-Atalay, Erin M O’Leary, Mariel Glass, Jennifer C. Houpy Szafran, Parker S. Woods, Angelo Y. Meliton, Obada R. Shamaa, Yufeng Tian et al. · 2025 · American Journal of Physiology-Lung Cellular and Molecular Physiology
PI3K/Akt/mTOR Pathway: A Growth and Proliferation Pathway
Daniel Cho, James Walter Mier, Micheal B. Atkins · 2009 · Humana Press eBooks
Hypoxia‐inducible factors – regulation, role and comparative aspects in tumourigenesis
Adam Espe Hansen, Annemarie Thuri Kristensen, Ian G. Law, Jesper Tranekjær Jørgensen, Svend Aage Engelholm · 2010 · Veterinary and Comparative Oncology
Transcriptome sequencing revealed differences in the response of renal cancer cells to hypoxia and CoCl2 treatment
Nadezhda Zhigalova, Artem V. Artemov, Alexander M. Mazur, Egor Prokhortchouk · 2015 · F1000Research
Current Trends in Cancer Therapy
Navjot Sekhon, Rekha Anjali Kumbla, Monica M Mita · 2016 · Elsevier eBooks
Antiangiogenic Therapy Using Sunitinib Combined with Rapamycin Retards Tumor Growth But Promotes Metastasis
Tao Yin, Sisi He, Tinghong Ye, Guobo Shen, Yang Wan, Yongsheng Wang · 2014 · Translational Oncology
Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Current Status and Future Applications
Allan Pantuck, GEORGE V. THOMAS, A.S. Belldegrun, Robert A. Figlin · 2006 · Seminars in Oncology
Impact of anti-angiogenic treatments on metastatic renal cell carcinoma
Nicola L. Ainsworth, Jean SZ Lee, Tim G Eisen · 2009 · Expert Review of Anticancer Therapy
Molecular and Metabolic Subtypes in Sporadic and Inherited Clear Cell Renal Cell Carcinoma
Maria Czyzyk-Krzeska, Julio Alberto Landero Figueroa, Shuchi Gulati, John T. Cunningham, Jarek Meller, Behrouz Shamsaei, Bhargav Vemuri, David R. Plas · 2021 · Genes
Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies
Devashish Mehta, Kajal Rajput, Dolly Jain, Avinash Bajaj, Ujjaini Dasgupta · 2024 · ACS Pharmacology & Translational Science
Targeting mTOR in mantle cell lymphoma: Current and future directions
Sonali M. Smith · 2012 · Best Practice & Research Clinical Haematology
Emetine Promotes von Hippel-Lindau-Independent Degradation of Hypoxia-Inducible Factor-2α in Clear Cell Renal Carcinoma
Hyesik Kong, Sunmin Lee, Kristin E. Beebe, Bradley T. Scroggins, Gopal Nand Gupta, Min-Jung Lee, Yunjin Jung, Jane B. Trepel, Leonard Μ. Neckers · 2010 · Molecular Pharmacology
Potential of Drug Efficacy Evaluation in Lung and Kidney Cancer Models Using Organ-on-a-Chip Technology
Seong-Hye Hwang, Sang‐Chul Lee, Jee Yoon Park, Jessie Sungyun Jeon, Young‐Jae Cho, Sejoong Kim · 2021 · Micromachines
Update on the Epidemiology and Biology of Renal Cortical Neoplasms
Sean Collins, James McKiernan, Jaime Landman · 2006 · Journal of Endourology
Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy
Mark Frederick McCarty, Jorge Barroso-Aranda, Francisco Contreras · 2010 · Medical Hypotheses
Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055
Heather G. Keen, Sally‐Ann Ricketts, Juliana Maynard, Armelle Logié, Rajesh Odedra, Aoife M. Shannon, Stephen R. Wedge, Sylvie Mireille Guichard · 2013 · Molecular Imaging and Biology
Second-line therapy for refractory renal-cell carcinoma
Fable Zustovich, Giuseppe Lombardi, Ornella Nicoletto, Davide Pastorelli · 2011 · Critical Reviews in Oncology/Hematology
Von Hippel-Lindau syndrome: molecular mechanisms of the disease
María José Calzada · 2010 · Clinical & Translational Oncology
d-Glucosamine down-regulates HIF-1α through inhibition of protein translation in DU145 prostate cancer cells
Jee-Young Park, Jong‐Wook Park, Seong‐Il Suh, Won‐Ki Baek · 2009 · Biochemical and Biophysical Research Communications
Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences
Consuelo Buttigliero, Simona Allis, Marcello Tucci, Clizia Zichi, Gianmarco Leone, Rosario Francesco Di Stefano, Maria Grazia Ruo Redda, Umberto Ricardi, Giorgio V. Scagliotti, Massimo Di Maïo et al. · 2018 · Cancer Treatment Reviews
Are Tyrosine Kinase Inhibitors Still Active in Patients With Metastatic Renal Cell Carcinoma Previously Treated With a Tyrosine Kinase Inhibitor and Everolimus? Experience of 36 Patients Treated in France in the RECORD-1 Trial
Aurore Blesius, Benoit Beuselinck, Christine Chevreau, Alain Ravaud, Frédéric Rolland, Stéphane Marie. Oudard, Bernard J. Escudier · 2013 · Clinical Genitourinary Cancer
The Role of Capillaries in the Lesser Ailments of Old Age and in Alzheimer’s Disease and Vascular Dementia: The Potential of Pro-Therapeutic Angiogenesis
Charles T. Ambrose · 2016 · Journal of Alzheimer s Disease
Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
Bryce Raymon Christensen, Yasmin Hajja, Vadim S. Koshkin, Pedro Coelho Barata · 2021 · Current Treatment Options in Oncology